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Abstract
Background: Leishmaniasis and Chagas disease are life-threatening illnesses caused by the protozoan parasites
Leishmania spp. and Trypanosoma cruzi, respectively. They are known as “neglected diseases” due to the lack of
effective drug treatments and the scarcity of research work devoted to them. Therefore, the development of novel
and effective drugs is an important and urgent need. Natural products are an important source of bioactive
molecules for the development of new drugs. In this study, we evaluated the activity of enhydrin, uvedalin and
polymatin B, three sesquiterpene lactones (STLs) isolated from Smallanthus sonchifolius, on Leishmania mexicana
(MNYC/BZ/62/M) and Trypanosoma cruzi (Dm28c). In addition, the in vivo trypanocidal activity of enhydrin and
uvedalin and the effects of these STLs on parasites’ ultrastructure were evaluated.
Methods: The inhibitory effect of the three STLs on the growth of L. mexicana amastigotes and promastigotes as
well as T. cruzi epimastigotes was evaluated in vitro. The changes produced by the STLs on the ultrastructure of
parasites were examined by transmission electron microscopy (TEM). Enhydrin and uvedalin were also studied in a
murine model of acute T. cruzi infection (RA strain). Serum activities of the hepatic enzymes alanine
aminotransferase, aspartate aminotransferase and lactate dehydrogenase were used as biochemical markers of
hepatotoxicity.
Results: The three compounds exhibited leishmanicidal activity on both parasite forms with IC50 values of 0.42–0.
54 μg/ml for promastigotes and 0.85–1.64 μg/ml for intracellular amastigotes. Similar results were observed on T.
cruzi epimastigotes (IC50 0.35–0.60 μg/ml). The TEM evaluation showed marked ultrastructural alterations, such as an
intense vacuolization and mitochondrial swelling in both L. mexicana promastigotes and T. cruzi epimastigotes
exposed to the STLs. In the in vivo study, enhydrin and uvedalin displayed a significant decrease in circulating
parasites (50–71%) and no signs of hepatotoxicity were detected.
Conclusions: Enhydrin, uvedalin and polymatin B possess significant leishmanicidal and trypanocidal activity on
different parasite stages. These results show that these compounds may provide valuable leads for the
development of new drugs against these neglected parasitic diseases.
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Background
Leishmaniasis is a poverty-associated, diverse and com-
plex disease presenting several different forms, of which
cutaneous leishmaniasis (CL) and visceral leishmaniasis
(VL) are the most common. This disease is caused by
different species of the kinetoplastid protozoan genus
Leishmania, which is transmitted to humans by phlebo-
tomine sand flies. Leishmaniasis occurs in 98 countries,
where 300,000 new cases of VL and 1,000,000 new cases
of CL are reported each year, with 350 million people
living at risk [1]. The incidence of CL is increasing in
Latin America and, despite it not being a life-threatening
disease, it causes disability and leaves permanent scars
that can lead to social prejudice [2]. Current treatments
for CL are unsatisfactory; frequently, they are associated
with significant failure rates and considerable toxicity.
The World Health Organization recommends the use of
pentavalent antimonials as first-line drugs [3]. However,
these compounds are toxic and have poor effectiveness in
the treatment of chronic manifestations of CL. Alternative
treatments include the use of liposomal amphotericin-B
(ANF); however, this drug cannot be widely employed due
to its high cost and delivery requirements [4].
Chagas disease or American trypanosomiasis is a life-
threatening illness caused by the parasite Trypanosoma
cruzi. Annually, 56,000 new cases are reported in the
Americas, and it is estimated that this disease causes
about 12,000 deaths per year [5]. According to the
Global Burden of Disease Study, Chagas disease was
responsible for 550,000 disability adjusted life years in
2010 [6].
In many regions of Latin America, T. cruzi and
Leishmania spp. infections overlap. Both species have
close phylogenetic relationships [7] and therefore in
these regions, it is sometimes difficult to differentiate
serologically between Chagas disease and American CL
due to antigenic cross-reactivity [8–10]. Trypanosoma
cruzi strains are defined according to six different
discrete typing units (DTUs TcI–TcVI) [11] which differ
in virulence, pathogenicity, drug resistance, immune re-
sponse, parasitaemia levels and tissue tropism [12–14].
Currently, there are two therapeutic options for the
treatment of Chagas disease: the nitroheterocyclic com-
pounds benznidazole (BNZ) and nifurtimox. These
drugs were marketed in the 1970s but only BNZ has
been recently approved by the Food and Drug Adminis-
tration for use in children aged 2 to 12 years old with
Chagas disease using the Accelerated Approval pathway
[15]. BNZ is used as first line treatment because it has a
better side-effect profile than nifurtimox. Nevertheless,
both drugs have low or no efficacy during the chronic
stage of the illness, have regional variations of effective-
ness due to drug-induced resistance, and they present
severe side effects that lead to the interruption of the
treatment in a high percentage of patients [16]. Thus,
there is an urgent need for the development of new drugs
for the treatment of leishmaniasis and Chagas disease.
In the search of new therapeutic agents, natural
products are an important source of bioactive molecules
for the development of new drugs or as lead molecules
which might enter into the drug discovery pipeline [17].
The importance of natural compounds, especially as
antibacterial, antifungal, antiparasitic and antiviral
agents, has been extensively reviewed by Newman &
Cragg [18]. In the search for bioactive compounds with
antiprotozoal activity [19–21], we have studied different
plants, mainly from the family Asteraceae.
Smallanthus sonchifolius (Asteraceae) is a perennial
species of South America commonly known as “yacón”.
The tuberous roots of this plant have a sweet taste and
are used as traditional food and eaten either raw alone
or in fruit salads. They can be also boiled, baked or used
to prepare beverages, syrup, juice or marmalade. The
young stems are used as a vegetable similar to celery.
The antidiabetic properties of S. sonchifolius are attrib-
uted to the leaves which are dried and used to prepare
infusions [22, 23].
Literature data indicate that the leaves of this plant
have antibacterial, anti-inflammatory and antifungal
properties [24–26]. We have previously reported the
cytotoxicity of six sesquiterpene lactones (STLs) isolated
from S. sonchifolius in leukaemia and pancreatic cancer
cells. Interestingly, one of those STLs was reported for
the first time in nature [27], whilst the in vitro trypano-
cidal activity of the STLs enhydrin, uvedalin and poly-
matin B has been previously reported by our group [28].
In view of the results obtained, and considering the
current drawbacks related to the treatment with trypa-
nocidal drugs, this study was aimed at determining
whether the STLs enhydrin and uvedalin are active in an
animal model of the infection. In addition, the in vitro
efficacy of the compounds against Leishmania mexicana
and the susceptibility of a different strain of T. cruzi to
the three STLs were investigated. Finally, the ultrastruc-
ture alterations induced by these STLs on T. cruzi and
L. mexicana were also studied by TEM.
Methods
General experimental procedures
Infrared (IR) spectra were recorded in an Alpha FT-IR
Spectrometer (Bruker, Ettlingen, Germany). Proton nu-
clear magnetic resonance (1H-NMR) and carbon NMR
(13C-NMR) experiments were performed in a Bruker DRX
400 MHz spectrometer set at 400 MHz (1H) or 100 MHz
(13C) and electron ionization-mass spectrometry (EI-MS)
experiments were performed on a ThermoQ Exactive
mass spectrometer (Thermo Scientific, West Palm Beach,
FL, USA).
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Plant material
The aerial parts of S. sonchifolius (clone LIEY 97–2),
were collected in the province of Tucumán, Argentina
(Centro Universitario “Horco Molle”, University of
Tucumán 26°47'S, 65°19'W, 547 m a.s.l.) in April 2013.
All procedures were performed in agreement with insti-
tutional guidelines from IQUIMEFA (UBA-CONICET).
A voucher specimen (LIL 607176) is deposited at the
Herbarium of Instituto “Miguel Lillo”, Tucumán,
Argentina.
Extraction procedure, isolation and identification of the STLs
Smallanthus sonchifolius leaves were processed by soak-
ing in dichloromethane at room temperature for 30 min
as previously described [28]. This extract was subjected
to a bioassay-guided fractionation by sequential silica gel
(70–230 mesh; Macherey-Nagel, Düren, Germany) col-
umn chromatography using a gradient of n-hexane
(2 × 250 ml), n-hexane-ethyl acetate (1:1) (2 × 250 ml),
ethyl acetate (2 × 250 ml), ethyl acetate-methanol (1:1)
(2 × 250 ml), and methanol (2 × 250 ml) as mobile
phase. From this fractionation, three bioactive com-
pounds were isolated and identified by comparison of
the spectral data (IR, EI-MS, 1H-NMR and 13C-NMR)
with previously published reports [27, 28] as the STLs
enhydrin, polymatin B and uvedalin. Purity analysis was
carried out by High Performance Liquid Chromatog-
raphy (Waters® 600 chromatographer with a photodiode-
array detector, Massachusetts, USA) on a RP-18 column.
The purity of each compound was invariably > 95%.
Parasites and media
Leishmania mexicana promastigotes (MNYC/BZ/62/M
strain) were kindly provided by Berta Franke de Cazzulo
(IIB-INTECH; CONICET-UNSAM). Parasites were
grown in either Grace or Diamond medium supple-
mented with 10% foetal bovine serum (FBS). Leish-
mania promastigotes at the logarithmic phase were
used in most assays, and at the stationary phase for
macrophage infection. Trypanosoma cruzi epimasti-
gotes (Dm28c strain) were grown and maintained in
culture according to Sülsen et al. [19]. Bloodstream
trypomastigotes of T. cruzi (RA strain) were obtained
as previously described [20].
Animals
Inbred male CF-1 and female C3H/HeN mice were
nursed at the Department of Microbiology, School of
Medicine (University of Buenos Aires). Animals were
housed, kept and provided with water and a standard
diet [20].
Evaluation of antiprotozoal activity in axenic culture
parasites
Leishmania promastigotes and T. cruzi epimastigotes
growth inhibition was evaluated by direct counting in a
Neubauer chamber. Stock solutions of test compounds
were prepared in dimethyl sulfoxide (DMSO). The final
concentration of DMSO did not exceed 1%. The assay
was performed by duplicate, in the presence of 0, 1, 2.5,
5 or 10 μg/ml of each compound. Cell density was
adjusted to 2.0–2.5 × 106 parasites/ml and cells were
cultured in the presence of each compound for 24 and
48 h. ANF (1 μg/ml, ICN) or BNZ (5 μg/ml, Elea) were
used as positive controls for Leishmania and T. cruzi
growth inhibition, respectively. A solution of 1%
DMSO was used as negative control. The percentage
of inhibition was calculated at 48 h as: 100 –
[(Number of treated parasites)/(Number of untreated
parasites)] × 100.
Chemotherapeutic effects of enhydrin and uvedalin on
the intracellular amastigote forms of Leishmania
Murine peritoneal macrophages were isolated from 4 to
6-week-old CF-1 mice (n = 3) by peritoneal lavage with
5 ml of ice-cold Roswell Park Memorial Institute
medium (RPMI) 1640 (Gibco, Rockville, MD, USA) con-
taining 100 IU/ml penicillin, 100 μg/ml streptomycin
and 10% FBS (complete RPMI). Cells (1.5 × 105/well)
were seeded on glass coverslips inside 24- well plates
(Corning Inc., Corning, NY, USA) and incubated over-
night at 37 °C in 5% CO2. Non-adherent cells were
washed away and the adherent macrophages were in-
fected for 4 h with stationary-phase Leishmania promas-
tigotes at a parasite/macrophage ratio of 5:1. After
removal of extracellular parasites, cultures were incu-
bated for 72 h in the presence of seven different concen-
trations of enhydrin or uvedalin ranging from 0 to
50 μg/ml. ANF was used as a positive control (0 to
0.6 μg/ml). The number of infected cells and the number
of amastigotes per 100 cells were calculated by counting
at least 200 cells per Giemsa-stained coverslip. Results
were expressed as % anti-amastigote activity (%
AA) = [1 – (Number amastigotes/100 treated cells) /
(Number amastigotes/100 untreated cells)] × 100.
IC50 values were determined for each compound.
Cells were observed and photographed with a light
microscope with an Olympus (Hachioji, Japan) micro-
photographic system at 400× magnification.
In vivo trypanocidal activity of enhydrin and uvedalin
Groups of male C3H/HeN mice (6–10 mice/group,
6–8 week-old, 23–25 g weight), were inoculated with
5 × 103 bloodstream T. cruzi trypomastigotes (RA
strain) by the intraperitoneal (ip) route. After infection
was established, on day 7 post-infection (pi), different
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groups of mice were treated with 1 mg/kg of body weight/
day of either enhydrin, uvedalin or BNZ by the ip route
for five consecutive days as previously reported [21]. Stock
solutions of the compound samples were prepared in
ethanol:water (1:1) and dilutions were made in PBS
(pH 7.2). Another group of mice was treated with PBS
(pH 7.2) as negative control. The final concentrations of
ethanol did not exceed 0.1%. The parasitaemia was indi-
vidually monitored every 2 days from day 5 to day 40 pi,
in 5 μl of blood, by direct microscopic counting of para-
sites in a Neubauer chamber after the lysis of red cells.
Body weight and clinical conditions, including physical ap-
pearance, were recorded every other day. Mortality was
recorded every day until the end of the experiment
(100 days) and the results were expressed as percentage of
surviving animals [20].
In vivo toxicity study
The in vivo toxicity of enhydrin and uvedalin was
assessed in groups of 5 uninfected male C3H/HeN mice
with a five-day course of daily ip injection of 1 mg/kg of
body weight/day of the compounds. Stock solutions of
the samples were prepared in ethanol:water (1:1) and
dilutions were made in PBS (pH 7.2). PBS was also
employed as negative control. After the fifth dose, blood
samples were collected and the serum separated. Alanine
aminotransferase (ALT), aspartate aminotransferase
(AST) and lactate dehydrogenase (LDH) levels were
used as biochemical markers to evaluate hepatotoxicity.
Assays were carried out by ultraviolet spectrophotom-
etry (Wiener Lab, Buenos Aires, Argentina).
Transmission electron microscopy
Leishmania promastigotes and T. cruzi epimastigotes
were treated with 2.5 and 0.5 μg/ml of enhydrin, poly-
matin B or uvedalin for 24 h. Ultrathin sections of para-
site cells treated with these compounds were observed
with a transmission electron microscope as previously
described [20].
Statistical analysis
Statistical analyses were carried out using GraphPad
Prism 5 software (GraphPad, San Diego, CA, USA). In
experiments with more than two groups of mice, data
were analysed using one-way ANOVA with Dunnett’s
post-test. If necessary, a logarithmic transformation was
applied to obtain data with a normal distribution and
50% inhibitory concentration (IC50) values were esti-
mated by linear regression as previously described [20].
A P-value lower than 0.05 was considered significant.
Results were expressed as means ± SEM for each
group. In survival experiments, curves were generated
with GraphPad Prism 5 software and analysed with
the log-rank test.
Results
In vitro activity against axenically cultured parasites
The effect of the STLs enhydrin, polymatin B and uveda-
lin (Fig. 1) on the growth of L. mexicana promastigotes
is shown in Fig. 2. The three compounds exhibited leish-
manicidal activity with IC50 values of 0.43 μg/ml
(0.92 ± 0.18 μM), 0.45 μg/ml (1.04 ± 0.25 μM) and
0.42 μg/ml (0.93 ± 0.2 μM) for enhydrin, polymatin B
and uvedalin, respectively, with no significant differences
among them. The inhibitory activity of the compounds
on T. cruzi epimastigotes of DTU I (Dm28c strain, Fig. 3)
was also evaluated. Enhydrin, polymatin B and uvedalin
were active with IC50 values of 0.36 μg/ml
(0.78 ± 0.22 μM), 0.60 μg/ml (1.38 ± 0.5 μM) and
0.35 μg/ml (0.79 ± 0.12 μM), respectively. All the com-
pounds were more effective than BNZ (IC50 = 10.6 μM)
and ANF (IC50 = 2 μM), used as positive control drugs
for T. cruzi and L. mexicana, respectively.
Growth inhibition of the intracellular stage of
Leishmania spp.
The chemotherapeutic effect of enhydrin and uvedalin
was also studied on amastigotes. The inhibitory activity
of the compounds is shown in Fig. 4. The IC50 values for
enhydrin and uvedalin were 1.64 μg/ml (3.66 μM) and
0.85 μg/ml (1.89 μM), respectively. Amphotericin B pre-
sented an IC50 value of 3.35 ng/ml (3.62 nM) for amasti-
gotes after 72 h of treatment.
In vivo trypanocidal activity of enhydrin and uvedalin
Untreated mice inoculated with T. cruzi trypomastigotes
(RA strain) displayed high parasitaemia levels with 100%
mortality on day 22–25 post-infection (pi). When ani-
mals were treated with either enhydrin or uvedalin (for 5
consecutive days), a significant reduction of circulating
parasites during the acute phase of T. cruzi infection
was observed (Fig. 5a, b). Trypomastigotes were detected
in all animals by 7 days pi, peaking on day 14 pi and
declining gradually to low values by day 35 pi in the
surviving animals. The mean peak parasitaemia for un-
treated mice was 1.0 ± 0.2 × 107 parasites/ml. Uvedalin
and enhydrin-treated mice presented a 50 and 71% re-
duction in the number of blood parasites, respectively
(on day 14 pi), similar to the reduction observed in the
BNZ-treated group (64%). No significant differences
were observed between treatments (Mann-Whitney U-
test uvedalin vs enhydrin, U = 8.5, P = 0.27; uvedalin vs
BNZ, U = 14, P = 0.57; and enhydrin vs BNZ, U = 12,
P = 0.65).
Those animals presenting higher number of circu-
lating parasites also presented a higher body weight
loss (Fig. 5c). Untreated animals presented a 6% body
weight loss during the peak of parasitaemia, followed
by death. Enhydrin and uvedalin-treated mice lost less
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than 1.5% of their body weight. The clinical condition
of all animals improved during the treatment as well
as that of animals treated with BNZ. By the end of
the experiment (100 days pi), 57 and 52% of uvedalin
and enhydrin-treated mice had survived (Fig. 5d).
Regardless of the treatment, all surviving animals
appeared physically healthy and displayed an active
behaviour. All mice lost weight around the maximum
parasitaemia time, especially non-treated animals, with
no statistical differences between treated groups.
In vivo toxicity of enhydrin and uvedalin
No signs of toxic effects were observed in uninfected
mice during the 5 days of treatment with enhydrin and
uvedalin. No significant body weight drop or death in
any treatment group of uninfected mice was observed
either. No significant differences were observed in AST,
LDH and ALT serum activities between control and
treatment groups.
Transmission electron microscopy (TEM)
Ultrathin sections of T. cruzi epimastigotes and Leish-
mania promastigotes treated with enhydrin, polymatin B
and uvedalin were analysed by TEM. Results demon-
strated that Leishmania parasites were more sensitive to
the compounds than T. cruzi, even at doses as low as
0.5 μg/ml. In Leishmania, the presence of multilamellar
structures resembling cytoplasmic bodies and parasite
lysis were observed (Fig. 6). At higher doses (2.5 μg/ml),
both L. mexicana and T. cruzi suffered major ultrastruc-
tural alterations, such as intense vacuolization, with a
higher proportion of parasites being destroyed (data not
Fig. 1 Chemical structures of enhydrin, uvedalin and polymatin B
Fig. 2 Effect of enhydrin (a), polymatin B (b) and uvedalin (c) on the growth of L. mexicana promastigotes at the indicated concentrations, after
24 h and 48 h of treatment. Symbols represent mean ± SEM from three independent experiments. ANF (1 μg/ml) was used as positive control
and 1% DMSO was used as negative control. (*) above the means indicate significant differences between control vs all treatments at each time
point (P ≤ 0.05)
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shown). In addition, mitochondrial swelling was
observed on T. cruzi after the treatment with 2.5 μg/ml
of uvedalin.
Discussion
In earlier studies, we have reported the antiparasitic
activity of different STLs isolated from Argentine medi-
cinal species [19–21, 28]. There are over 5000 known
structures of these naturally occurring compounds
which are mainly present in members of the family
Asteraceae. Their vast chemical diversity has been
related to a wide range of biological activities ranging
from antitumour, antibacterial, antihelminthic, uterus
contracting, antimalarial and neurotoxic activity [29].
Artemisinin, a STL isolated from the leaves of the Chinese
plant Artemisia annua, is considered the current gold-
Fig. 3 Effect of enhydrin (a), polymatin B (b) and uvedalin (c) on the growth of T. cruzi epimastigotes (Dm28c) at the indicated concentrations,
after 24 and 48 h of treatment. Symbols represent mean ± SEM from three independent experiments. BZN (5 μg/ml) was used as positive control
and 1% DMSO was used as negative control. (*) above the means indicate significant differences (P ≤ 0.05) between control and compounds
under study at 24 (a) and 48 h (b)
Fig. 4 Inhibitory activity of uvedalin and enhydrin on L. mexicana amastigotes. Murine peritoneal macrophages were infected with stationary-phase
Leishmania promastigotes (parasite:cell ratio 5:1). After washing out the unbound parasites, STLs were added at concentrations ranging from 0 to
50 μg/ml. Results were expressed as % antiamastigote activity (% AA). Inset: inhibitory activity of amphotericin B on L. mexicana intracelular
amastigotes. Values represent the mean ± SEM. No significant differences were observed between both STLs
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standard treatment for malaria, being the most relevant
example of a STL with antiprotozoal activity [30].
In this study, we have demonstrated the leishmanicidal
and trypanocidal activities of enhydrin, uvedalin and
polymatin B, three STLs isolated from S. sonchifolius
that belong to the germacranolide group. Results showed
that the three compounds exhibited significant leishma-
nicidal activity against promastigotes of L. mexicana
(IC50 values = 0.42–0.54 μg/ml). A vast number of
natural products have been reported to show antileish-
manial activity [31, 32]. Our results are comparable to
other STLs, including those reported by us in previous
studies [19, 20]. Considering that amastigotes are the
clinically relevant stage of the parasite and that they are
present in mammalian hosts, including humans, we have
evaluated the activity of enhydrin and uvedalin on this
intracellular stage (polymatin B was not included due its
low content in the plant material). Both compounds
Fig. 5 In vivo trypanocidal activity of uvedalin and enhydrin. Mice were infected with 5 × 103 bloodstream trypomastigotes (RA strain) and
treated for 5 consecutive days, starting on day 7 pi with 1 mg/kg/day of uvedalin, enhydrin, BNZ or with an equivalent volume of PBS (negative
control). a Circulating parasites on the peak of parasitaemia (day 14 pi). b Parasitaemia curve. c Percentage of body weight loss on the peak of
parasitaemia (on day 14 pi). d Survival curve during the acute infection period. Results are shown as mean ± SEM and are representative of 3
independent experiments (*P < 0.05, **P < 0.01 vs negative control)
Fig. 6 Ultrastructural effects of the STLs on L. mexicana promastigotes. Parasites were incubated with medium alone (a) as negative control or
0.5 μg/ml of either enhydrin (b), polymatin B (c) or uvedalin (d). Magnification: 3200× (b-d); 3600× (a). Scale-bar: 1 μm. Abbreviations: N nucleus,
Mc mitochondria, F flagellum, V vacuoles, GI glycosomes, mL multilamellar structure; **, destroyed parasite
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inhibited amastigotes growth with IC50 values of 1.64 and
0.85 μg/ml, respectively. To date, no reports have de-
scribed the antileishmanial activity of these compounds.
In a previous study, we have described the isolation of
enhydrin, uvedalin and polymatin B by bioassay-guided
fractionation from a crude extract of S. sonchifolius and
the activity of these compounds on the RA strain of T.
cruzi [28] that belongs to the DTU VI [11]. Since T.
cruzi is genetically highly diverse, here we investigated
the in vitro activity of these germacranolides on a strain
belonging to DTU I (Dm28c), which is the most
frequent of all T. cruzi DTUs in the Americas [12].
Although DTU VI is by far the most commonly used
strain for in vitro assays [33], DTU I is the most com-
mon genotype associated with acute Chagas disease, and
often found in chronic chagasic patients with cardiomy-
opathy [11]. Our results indicated that enhydrin,
polymatin B and uvedalin are active against T. cruzi epi-
mastigotes belonging to the Dm28c strain (DTU I).
These compounds proved to be more active than BNZ
(Fig. 3). The activity of the STLs on different strains of
T. cruzi is important for the development of new antic-
hagasic drugs since the variability in the morbidity of
the disease is believed to be associated with the high
complexity of parasite populations. Moreover, co-
infections with Leishmania spp. and T. cruzi have been
reported [8–10] and thus far, a single drug that is active
against both parasites is not available.
Numerous plant metabolites have been shown to
possess in vitro activity against T. cruzi; however, in vivo
bioassays are scarce [34]. In this work, we have demon-
strated that the administration of 1 mg/kg/day of enhy-
drin or uvedalin to T. cruzi-infected mice produce a
significant reduction in parasitaemia, similar to the re-
duction observed in BNZ-treated animals. The treatment
with enhydrin or uvedalin prevented the weight loss
observed in PBS-treated mice. Although STLs seemed to
be more effective than BNZ in terms of body weight loss
prevention, no statistically significant differences were
observed between them. It should be noted that
although animals were treated for only five days with
doses 2 log lower than those used in the conventional
treatment with BNZ in the murine model, a significant
decrease of mortality was observed in treated mice, as
compared to the control group.
TEM ultrastructural analyses were carried out to
assess the effect of the three STLs on L. mexicana and
T. cruzi. The TEM evaluation demonstrated the exist-
ence of marked ultrastructural alterations in both para-
sites. The multilamellar structures, observed in L.
mexicana promastigotes treated with 0.5 μg/ml of each
compound could correspond to autophagic vacuoles that
are probably part of an underlying mechanism of para-
site death. On the other hand, after a 2.5 μg/ml
treatment with enhydrin and polymatin B, an intense
cytoplasmic vacuolization in both parasite species was
observed. Uvedalin caused mitochondrial swelling in T.
cruzi epimastigotes (data not shown). This finding is in
line with those obtained with other STLs like psilosta-
chyin [35] and parthenolide [36]. The fact that kineto-
plastids have a single branched mitochondrion makes
this organelle an attractive drug target [37]. Even though
the mechanism of action of these STLs has not yet been
determined, these compounds could exert their antipro-
tozoal effect through the generation of reactive oxygen
species (ROS) [38, 39]. Further studies are needed to
confirm this hypothesis.
In this study, drug-induced liver injury was assessed
through the measurement of biomarkers. When unin-
fected animals were treated with the compounds, no
signs of toxicity were observed. Moreover, considering
the CC50 values previously reported by our group [28],
the selectivity index values (SI) for Leishmania amasti-
gotes were 12.7 and 24.8 for enhydrin and uvedalin,
respectively. These data indicate that these compounds
show good selectivity when tested against mammalian
cells.
BNZ and nifurtimox can have different adverse effects,
with adults being more susceptible than children.
Furthermore, some patients are prone to treatment
discontinuation due to the appearance of such severe
adverse events [40]. These issues are relevant, since an
intense debate still exists regarding the parameters for
treatment success in Chagas disease.
Conclusion
In conclusion, the leishmanicidal activity of enhydrin,
uvedalin and polymatin B, on different forms of the par-
asites has been demonstrated for the first time. Further
to this, we have demonstrated the trypanocidal activity
of these compounds on a DTU I strain of T. cruzi as
well as its in vivo trypanocidal potential. TEM studies
revealed important ultrastructural alterations in T. cruzi
and Leishmania parasites treated with the compounds.
The dual leishmanicidal and trypanocidal activities
shown by enhydrin and uvedalin could be an interesting
advantage. Thus, these STLs could be considered as
promising lead compounds for the development of new
therapies for the treatment of Chagas disease and
leishmaniasis.
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